TOP2B and glioblastoma: Nevertheless, our results provide a novel rationality for blocking Top2β activity in GBM therapy, extending the knowledge of NMDAR signaling pathways in GBM cells, which may also help to identify therapeutic targets in NMDAR signaling in other tumors expressing NMDARs.